How GLP-1 Access Actually Works in Ireland

Ireland's medicines regulator is the Health Products Regulatory Authority (HPRA), but for a European Commission-authorised medicine, the HPRA does not run a second, separate approval process the way the UK's MHRA does after Brexit. The European Medicines Agency (EMA) assesses centrally authorised medicines once for the whole European Union, the European Commission issues one authorisation, and it is legally valid in Ireland the day it is granted. That makes the licensing question for most of these brands more straightforward than it is in Britain. What is not straightforward, and is currently narrower than the UK's NHS position, is whether the Health Service Executive (HSE) will pay for any of it.

Which of the nine brands are available in Ireland

Ozempic, Rybelsus, Saxenda, Victoza and Trulicity all hold European Commission marketing authorisations that apply in Ireland, and each has a current Summary of Product Characteristics (SPC) on medicines.ie, the Irish equivalent of the UK's electronic Medicines Compendium. These are the five brands with the longest track record here.

Tirzepatide is the same story as in the UK, for a different reason. Mounjaro was centrally authorised across the EU for type 2 diabetes in September 2022, and the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 9 November 2023 extending that same authorisation to weight management, for adults with a BMI of 30 or more, or 27 to 30 with a weight-related comorbidity. There is no separate European authorisation called Zepbound, and no Irish product sold under that name. Tirzepatide is Mounjaro here for both uses, the same practical outcome as the UK, but because Ireland is inside the EMA's single authorisation rather than needing its own MHRA sign-off, not because of an Irish decision to reuse one brand name.

Wegovy exists in Ireland as the weekly injection, on the market since March 2025. The once-daily 25 mg oral semaglutide tablet, sold under the Wegovy name, received European Commission marketing authorisation across the whole EU in July 2026 following a CHMP positive opinion in May 2026, so it is legally authorised for Ireland along with every other member state. Novo Nordisk's own statement on the approval said it was committed to launching the pill in more countries in the second half of 2026, which is a rollout schedule, not a same-day availability guarantee. At the time of writing this page does not have confirmation that the oral tablet is dispensed in Irish pharmacies yet, distinct from being licensed for Ireland.

Foundayo (orforglipron) is where Ireland currently sits behind the UK rather than level with it. The UK's MHRA authorised Foundayo on 10 August 2026, described in Lilly's own reporting as the first authorisation for orforglipron anywhere in Europe. That phrasing matters: it means no EU-wide European Commission authorisation existed at that date, so Foundayo has no Irish authorisation either, MHRA sign-off does not extend to Ireland, and an Irish reader will not find it in a pharmacy under any circumstance until the EU centralised procedure completes separately.

HSE funding: the GMS, the Long Term Illness Scheme and the Drugs Payment Scheme

Ireland does not have a NICE-style technology appraisal system with published phased BMI cohorts and rollout dates the way the UK does. Instead, a new medicine seeking public funding goes through a health technology assessment by the National Centre for Pharmacoeconomics (NCPE), an independent body that assesses comparative effectiveness and cost-effectiveness, and the HSE then makes the reimbursement decision. Compared with the UK's NICE process, the Irish process is slower on these medicines and its criteria are not published in the same phased, dated form NICE uses for tirzepatide.

For type 2 diabetes, the picture is closer to normal: Ozempic is reimbursed for people with diabetes under the Long Term Illness (LTI) Scheme, which covers approved medicines for a specified list of conditions including diabetes mellitus regardless of income, alongside the standard GMS medical card route. Off-label use of a diabetes-licensed brand for weight loss in someone without diabetes is not what the LTI Scheme or a medical card covers.

For weight management, Saxenda is currently the only one of the weight-licensed brands with any State funding, and it is funded on narrow terms: for patients with prediabetes and a high cardiovascular risk profile, under GMS and Drugs Payment Scheme criteria rather than the open licence. Wegovy and Mounjaro are not reimbursed under the GMS, LTI Scheme or Drugs Payment Scheme for weight management as of the time of writing. Both manufacturers have applications in with the HSE, Novo Nordisk having applied for Wegovy reimbursement covering adults and adolescents, and both are still going through the NCPE assessment and HSE decision process, with no confirmed approval date.

The scale of the decision is part of why it is slow. Public estimates put roughly 80,000 people in Ireland as potentially eligible for a State-funded weight-loss injection if criteria followed the UK's BMI-over-35-with-complications model, out of about 1.2 million adults classified as obese. Ireland's National Centre for Pharmacoeconomics director has been publicly clear that he does not expect every clinically eligible patient to receive these drugs through the community drug schemes even after a positive reimbursement decision, precisely because of that gap between the licensed population and what the State can afford to fund.

What private prescribing costs

Neither the HPRA nor the HSE publishes an official private retail price for these medicines, because that price is set commercially by individual pharmacies rather than fixed the way a reimbursed drug's price is. The figures below come from Irish news reporting rather than pharmacy or telehealth marketing, and they move: reported monthly prices have widened, not narrowed, as more brands and doses reached the Irish market.

When Wegovy launched in Ireland in March 2025, national reporting put the monthly cost at around €220. By later reporting the same year, the range quoted across doses had widened to roughly €240 to €355 a month. Mounjaro has been reported at a wider range still, from around €150 a month at a starting dose up to €275 to €595 a month at higher maintenance doses, reflecting how steeply pricing rises with dose on both brands.

A private prescription in Ireland, as in the UK, requires a genuine clinical assessment by a prescriber. A quoted headline price for the medicine itself is not the total cost of accessing it privately: consultation and follow-up fees are usually billed separately.

HPRA safety position: illegal and falsified supply

The HPRA has published rising figures on illegal weight-loss medicines entering Ireland outside the legitimate pharmacy supply chain. GLP-1 product seizures rose from 40 units in 2022, to 568 units in 2023, to 1,582 units in 2024, part of a broader total of just over one million dosage units of illegal medicines seized in 2024 across all categories, a 14% increase on 2023. The HPRA has also pursued enforcement action specifically involving Saxenda distributed outside the legitimate supply chain.

The HPRA's public safety message is the same one the MHRA gives in the UK: medicines obtained outside a registered pharmacy against a genuine prescription cannot be guaranteed to contain what the label says, and the health risk applies regardless of how convenient or cheap the source looks. Buying any of these nine brands from an unregistered online seller carries that risk in Ireland exactly as it does in the UK.

The evidence, one row per claim

Questions people ask

Sources

1. European Medicines Agency, marketing authorisation overview
2. European Medicines Agency, EPAR: Mounjaro
3. medicines.ie, Irish product information register (HPRA-recognised)
4. European Medicines Agency, EPAR: Wegovy, corroborated by nordiskpost.com reporting on the European Commission approval and launch timeline
5. MHRA / GOV.UK press notice, orforglipron (Foundayo) authorisation
6. St Columcille's Hospital Centre for Obesity Management, pharmacotherapy guidance for health professionals
7. Irish Examiner, reporting on State-funded weight-loss injection eligibility
8. The Irish Times, Wegovy Irish market launch pricing report
9. RTE News, reporting on HPRA illegal medicines seizure figures